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ABSTRACT 
Studies have showed that phytochemicals present in fruit juices alter the oral bioavailability of drugs by inhibition of metabolising enzymes and 
transport proteins. The present study aimed to investigate the effect of Psidium guajava on the oral exposure of metoclopramide in rabbits. 
Pharmacokinetic parameters of metoclopramide were determined in rabbits following an oral (0.5mg/kg) administration of metoclopramide in 
the presence and absence of Psidium guajava (5mL/kg, given orally). Compared to the control group given metoclopramide alone, the combined 
use of Psidium guajava increased the oral exposure (AUC) of metoclopramide by 13% with a corresponding 177 % increase in Cmax and half-life 
(71%).  Furthermore, Tmax decreased from 2h to 1h which might have contributed to the elevated plasma drug concentration in the first two 
hours in the presence of Psidium guajava. There was a significant increase in Cmax (177%) and Ka (207%) which could be attributed to enhanced 
absorption via inhibition of P-gp resulting to increased bioavailability of the drug. In contrast, there was a significant decrease in elimination rate 
(88%) and a decrease in clearance rate (17%) attributable to inhibition of P450 enzymes (CYP2D6) by the phytochemical constituents. Psidium 
guajava enhanced the oral exposure of metoclopramide in rabbits likely by the inhibition of P-glycoprotein-mediated efflux during the intestinal 
absorption and inhibition of P450 enzyme system during metabolism, suggesting that the combined use of Psidium guajava or Psidium guajava-
containing diet with metoclopramide may require close monitoring for potential drug–diet interactions.  
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INTRODUCTION 
Adequate consumption of fruits and vegetables may reduce 
risk of some diseases like cancer.1 Certain phytochemical 
constituents in fruits and vegetables play an important role 
in significant food–drug interactions as they can affect drug 
absorption and disposition.2  The concomitant use of drug 
regimens with foods, herbs and nutrients predisposes an 
individual to drug-food/herb/fruit interactions.3 However, 
such interactions can result  to treatment failure or drug 
toxicities.4 Reports have indicated that a large proportion of 
the human population takes at least one pharmacologically 
active agent on a regular basis.  
Metoclopramide increases gastrointestinal motility and 
hence used as a prokinetic agent in the management  of  
drug-induced nausea and vomiting, diabetic gastroparesis 
and migraine headaches.5 Metoclopramide is well absorbed 
orally with a bioavailability of about 35% -100% and a half-
life of  3-4 h in man.5 
Psidium guajava L (Guava) is is an important staple fruit and 
medicinal plant cultivated and consumed in tropical and sub-
tropical countries.  It is known to be used in folk medicine 
around the globe.6,7  Psidium guajava contains a number of 
bioactive metabolites, such as phenolics, flavonoids, 
carotenoids, terpenoids, and triterpenes.8 Studies  have 
demonstrated the effects of guava extracts on drug 
transport. For example, Junyaprasert et al.9 showed that the 
fruit extract showed a potent inhibitory effect on P-gp -
mediated efflux in Caco-2 cells. They also indicated Psidium 
guajava to inhibit efflux transport in rat ileum suggestive of a 
possible interaction with P-gp substrates, such as digoxin, 
metoclopramide fexofenadine, indinavir, vincristine, 
colchicine, and paclitaxel in the small intestine.9 Therefore, 
our study investigated the effect of Psidium guajava on the 
pharmacokinetics of metoclopramide in rabbits to establish 
a preclinical fruit–drug interaction model. 
MATERIALS AND METHODS  
Materials 
Metoclopramide 10mg tablets USP (TEVA UK Limited, 
Eastbourne), methylated spirit (JHD, China), Sulphuric acid 
(99%), Sodium hydroxide and acetonitrile were obtained 
from Loba Chemie Pvt. Ltd. All other chemicals were of 
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reagent grade and all the solvents used were of high-
performance liquid chromatography (HPLC) grade.  
Preparation of Psidium guajava fruit 
Psidium guajava (guava) fruit (4 kg) was obtained from 
Choba, Port Harcourt, Nigeria in July. The sample was 
washed with clean tap water to remove dirt. The fruit was 
cut in small sizes and blended into a pulp with an electronic 
blender. 
Pharmacokinetic studies in rabbits 
Five local strains of health adult male rabbits (1.88 ± 0.7 kg) 
were used in the experiment. Animal ethics and proper 
handling methods were strictly adhered to. They were kept 
in the animal house of the department of Experimental 
Pharmacology and Toxicology, Faculty of Pharmaceutical 
Sciences, University of Port Harcourt, Nigeria for two weeks 
with free access to food and water before the experiment. 
Animals were fasted for 12 h prior to dosing and fed 
approximately 4 h post-dose.   
Experiment was carried out in two phases.10 In phase 1, each 
rabbit was given 0.5mg/kg of metoclopramide11 via oral 
route.  At pre-determined intervals of 0.5, 1, 2, 4, 5.5, and 7 h, 
blood samples were aseptically withdrawn from the 
marginal ear vein of the rabbits. Blood samples were 
collected into heparinized tubes, and centrifuged for 20 
minutes at 4,000 rpm. Aliquots of aspirated supernatant 
plasma were stored in a freezer until analyzed. The rabbits 
were again allowed free access to food and water for one 
week, during which the drug was assumed to have been 
removed from the animal system. The animals were then 
used for the next phase of the experiment. 
After the withdrawal of blood in the first phase, the rabbits 
were allowed a one-week drug 'wash-out' period before the 
commencement of the second phase and during this period, 
they had free access to food and water. It was assumed that 
all the drugs must have been eliminated within this period 
(T1/2 of metoclopramide = 3-4 h). The second phase started 
on the 8th day by the administration of 0.5mg/kg of 
metoclopramide orally to each rabbit and almost 
immediately, 5mL/kg of Psidium guajava pulp was 
administered orally to each rabbit. Blood samples were 
collected at similar time intervals and analyzed as described 
above. For each animal, the plasma concentration of 
metoclopramide was compared when the drug was 
administered alone to when it was administered 
concomitantly with Psidium guajava pulp.  The results were 
plotted as metoclopramide plasma concentration versus 
time to obtain a plasmatic curve, from which the 
pharmacokinetic parameters were calculated.  
HPLC Assay 
The plasma concentrations of metoclopramide were 
determined by the HPLC method reported by Cossu et al.  
(2008).  In a centrifuge test tube (10 ml), 250 µl of 1 M 
sodium hydroxide solution were added to 0.5 ml of plasma 
and the mixture was shaken on a vortex for 30 sec. 
Methylene chloride (5 mL) was added for drug extraction, 
and the mixture was stirred again for 2 min and centrifuged 
for 7 min at 4,000 rpm. Following centrifugation, the organic 
phase was transferred into a flask and evaporated at reduced 
pressure. The residue was reconstituted in 200 µl of 
acetonitrile and 0.01 N sulphuric acid 20/80 (v/v) solution, 
and sonicated for 5 min. The resultant turbid solution was 
centrifuged and the supernatant analyzed by HPLC (Rayleigh 
model LT 100) to determine the amount of metoclopramide 
extracted.  Separation and quantification were made on a 
250 4.6 mm (i.d.) ODS Waters XTerraTM column (5 mm 
particle size), preceded by a ODS XTerraTM , 5 mm, guard 
column (Waters, Milan, Italy). A 100 µL amount of calibration 
plasma standard or extracted sample was directly injected 
onto the column and eluted with mixtures of acetonitrile and 
0.01 N sulphuric acid solution 15/85 (v/v), at a flow rate of 
1.5 ml/min over 15 min. All determinations were performed 
at room temperature. Detection was accomplished using a 
variable UV/Vis detector (Hewlett- Packard 1050 series) set 
at 213 nm wavelength. Peak areas determined with a 3390 
integrator were used for data acquisition and processing 
(Hewlett- Packard, Waldbronn, Germany).  The calibration 
curve from the standard samples was linear over the 
concentration range of 0 to 100 ng/mL. The intra-day (n = 5) 
and inter-day (n = 5) coefficients of variation were less than 
15% and the detection limit was 1 ng/mL.  
Determination of Pharmacokinetic Parameters  
Plasma metoclopramide concentrations were analyzed by a 
non-compartmental method. The terminal elimination rate 
constant (Kel) was determined by log-linear regression. The 
apparent elimination half-life of the log-linear phase (T1⁄2) 
was calculated as 0.693/Kel. The area under the plasma drug 
concentration-time curve (AUC) was calculated from 0 to 7 
hours [AUC (0-7)] by the linear trapezoidal method. The AUC 
from time 0 to infinity [AUC (0-∞)] was calculated as AUC (0-
7) plus AUC from 7 hours to infinity [AUC (7- ∞ )], which was 
determined by dividing the final plasma drug concentration 
by Kel. Cmax and the time to reach Cmax (Tmax) were 
obtained directly from the experimental data.  Absorption 
rate constant (Ka) was derived by the method of back 
feathering from the graph of average serum concentration 
against time (absorption phase), using the relationship: 
slope =-0.43Ka.  The rate of clearance of metoclopramide 
from plasma was determined using the relation: CLT =Kel.Vd; 
where Vd is the volume of distribution.  
Statistical Analysis  
Results were expressed as mean ± standard error of mean. 
The significance of the difference between means of the 
control and test groups were determined using the Student's 
t-test.  A  P value of <0.05 was considered statistically 
significant.  
RESULTS 
Effect of Psidium guajava on the oral exposure of 
metoclopramide in rabbits 
Pharmacokinetic parameters in the rabbits after oral 
administration of metoclopramide in the presence or 
absence of Psidium guajava are summarized in Table 2 and 
the plasma concentration-time profiles are presented in 
Figure 1. A graph showing percentage change in 
concentration due to Psidium guajava administration is 
shown in Figure 2. Administration of Psidium guajava to 
rabbits caused an increase in the oral exposure of 
metoclopramide. There was about 13% increased in AUC (0-
7 h) in the group that received Psidium guajava and 
metoclopramide with a corresponding 177 % increase in 
Cmax.  Elimination rate decreased by 88% in the group that 
received Psidium guajava. Absorption rate constant 
increased by 207 % with a corresponding decrease in 
clearance rate (17%) resulting in drug accumulation. The 
half life of metoclopramide increased from 4.5 h to 7.7 h 
(71% increases). The time to reach peak plasma 
concentration was decreased from 2 h to 1h in the group that 
received Psidium guajava. This suggests that time to reach 
steady-state concentration may be reduced resulting in 
elevated plasma concentration of Psidium guajava. 
Percentage change in metoclopramide plasma 
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concentrations (0.5-7 h) are shown in figure 2. At 0.5 h, there 
was a 4 % decrease in concentration in the group that 
received Psidium guajava.  
 
Figure 1: Mean plasma concentration-time profiles of 
metoclopramide after an oral administration of 
metoclopramide (0.5 mg/kg) to rabbits in the presence 
and absence of Psidium guajava  (mean ± SEM, n = 5). 
MCP (metoclopramide, 0.5 mg/kg, p.o.); MCP + GV 
(combined use with 5 mL mg/kg of Psidium guajava). 
This increased by 193% and and 30  % at the 1 and 2 hours 
respectively. However at 4 and 5.5 h, there was a 67 % and 
103% decrease in concentration with a 2% increase at the 
7th hour. 
 
Figure 2: Percentage change in metoclopramide (MCP) 
plasma concentration (0-7 h) when co-administered 
with Psidium guajava. 
 
Table 1: Pharmacokinetic parameters of metoclopramide after an oral administration of metoclopramide (0.5 mg/kg) 
to rabbits in the presence and absence of Psidium guajava (mean ± SEM, n = 5).  *P < 0.05, compared to the control given 
metoclopramide alone. 
Parameters (unit) AUC ng/h/ml Tmax 
(hr) 
Cmax 
(ng/ml) 
Ka 
(hr) 
Cl 
(L/hr/kg) 
T½ 
(hr) 
Kel 
(hr) 
MCP 1230 ± 150.00 2± 0.05 278.5 ± 24.20 0.27+ 0.01 0.81±0.03 4.50 ±0.04  0.75 ±0.01 
MCP + Psidium guajava 1393± 170.00 1 ± 0.02 771.4 ± 31.10* 0.83 ± 0.02* 0.67± 0.01 7.70 ±0.08* 0.09± 0.01* 
% Change in AUC from 
control  
13% -50% 177% 207% -17% 71% -88% 
 
DISCUSSION 
Bioactive phytochemicals in fruits and vegetables can be 
beneficial for health. However, these phytochemicals can 
influence the pharmacological properties of drugs by altering  
their absorption characteristics via interactions with drug 
transporters and  drug-metabolizing enzymes.4 Efflux 
proteins found  in the intestinal epithelium such as P-
glycoprotein (P-gp) have been shown to reduce the 
absorption of certain  compounds that are substrates hence 
decreasing their bioavailability.12  In addition, the 
bioavailability of drugs could be decreased or increased 
when co-administered with other compounds that inhibit or 
induce enzymes that metabolise them. Studies have revealed 
that important constituents of certain fruits and vegetables 
significantly inhibit enzyme function in vitro.13   For example, 
studies have revealed that sevilla orange was shown to 
inhibit CYP3A4 and P-glycoprotein.14 Results from these 
studies implicated several furanocoumarins and 
bioflavonoids to be responsible for this inhibition.15 
Furthermore, grapefruit juice has been demonstrated to 
increase the oral bioavailability of some therapeutic agents 
such as  felodipine, nifedipine, saquinavir, and sildenafil.16-18 
This increase was attributed to inhibition of intestinal 
CYP3A4 drug metabolism by phytochemicals present in 
grape juice.17,18 Grapefruit was also reported to inhibit 
intestinal P-gp activity of certain drugs such as cyclosporine, 
hence increasing its oral bioavailability.13 These results 
strongly suggest that several furanocoumarins and 
bioflavanoids present in fruits are potent inhibitors of 
metabolising enzymes and drug transporters.  
Metoclopramide in is a gastro-prokinetic and  antiemetic  
drug which acts as an antagonist at D2 receptors in the 
chemoreceptor trigger zone in the central nervous system.19  
Metoclopramide was administered in a tablet form, and 
therefore its absorption and metabolism may be affected by 
the activity of the excretory transporters and drug 
metabolizing enzymes. Several researches have indicated 
that the absorption of metoclopramide in small intestinal 
mucosa was mainly mediated by P-gp, and metoclopramide 
was mainly metabolized by CYP2D6.19-21 Therefore, the 
potential drug–drug interaction of metoclopramide mediated 
by CYP450 and P-gp might happen.  
Important bioactive metabolites such as such as phenolics, 
flavonoids, carotenoids, terpenoids, and triterpenes, have 
been identified in Psidium guajava.8 Specifically, Psidium 
guajava contains flavonoids such as quercetin and phloretin 
which are known inhibitors of P-glycoprotein.4 Studies 
carried out by Junyaprasert et al.9 demonstrated the 
Amadi and Aghalibe                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(2):144-147 
ISSN: 2250-1177                                                                                  [147]                                                                                 CODEN (USA): JDDTAO 
inhibition of P-gp in rat ileum suggesting that Psidium 
guajava could interact with P-gp substrates in the small 
intestine. 
In our study, co-administration of metoclopramide with 
Psidium guajava fruit increased the oral exposure (AUC and 
Cmax) (Table 1) of metoclopramide in rabbits. The observed 
deviation in the pharmacokinetics of metoclopramide 
strongly suggests an inhibition of P-glycoprotein (P-gp) 
enzyme and P450 enzymes (CYP2D6) by the phytochemical 
constituents present in Psidium guajava. Inhibition of P-gp 
resulted to to enhanced absorption and consequently 
increased bioavailability. This may explain the observed 
significant increase in Cmax (177%), Ka (207%) and non-
significant increase in AUC (13%). On the other hand, 
inhibition of metabolism by P450 enzymes (CYP2D6) 
resulted in drug accumulation which could be responsible 
for the increase in half-life (71%) noted when Psidium 
guajava and the drug were administered together to the 
animals. This inhibition also explains the decreased 
elimination rate (88%) and decreased clearance (17%) 
observed when the drug was administered with the fruit. 
The alterations in the pharmacokinetic properties of 
metoclopramide could result in unwanted side effects and 
toxicities.  The plasma concentration of metoclopramide (in 
the group that received Psidium guajava) increased 
maximally at 1 hour (193%) (Figure 2) and reduced 
afterwards indicative of the point of maximal inhibitory 
effect on P-gp. Considering the therapeutic importance of 
metoclopramide and its relative cheapness and availability, a 
possible co-administration may occur in patients. 
Our data demonstrates preliminary evidence of the 
interaction between Psidium guajava and metoclopramide 
but the clinical significance of this is yet to be fully evaluated. 
In our opinion, Psidium guajava should be consumed with 
caution by patients taking metoclopramide to avoid 
toxicity/adverse effects of the drug. Furthermore, a large 
number of drugs are substrates for P-gp, the concomitant use 
of Psidium guajava or Psidium guajava-containing diets may 
provide some therapeutic benefits to enhance the 
pharmacokinetic features of poorly absorbable P-gp 
substrates.  
CONCLUSION 
Psidium guajava  enhanced the oral exposure of 
metoclopramide possibly by the inhibition of P-gp-mediated 
efflux during intestinal absorption and inhibition of P450 
enzymes (CYP2D6) during metabolism. This suggests  that 
the combined use of Psidium guajava or Psidium guajava- 
containing diet with metoclopramide may require close 
monitoring for potential drug–diet interactions. 
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